Sigyn Therapeutics, Inc. Operating Income Loss

• Sigyn Therapeutics, Inc. showed a decrease of -2.6% in Operating Income Loss from 2023 to 2024.
• This data is from Sigyn Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
• XBRL data for this metric is available from 2014 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2014 to 2024), Sigyn Therapeutics, Inc.'s Operating Income Loss has declined by 550.1%.
• Historical annual values: Fiscal year 2024: -$2.52 million | Fiscal year 2023: -$2.46 million | Fiscal year 2022: -$2.15 million | Fiscal year 2021: -$2.01 million | Fiscal year 2020: -$916.4 thousand | Fiscal year 2019: -$518.0 thousand | Fiscal year 2018: -$1.00 million | Fiscal year 2017: -$2.03 million | Fiscal year 2015: -$2.25 million | Fiscal year 2014: -$387.5 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026